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circulatory death donation may prevent ischemic 
cholangiopathy and improve graft survival























































Following	 withdrawal	 of	 life‐supporting	 treatment	 in	 a	 potential	













































namely	 early	 allograft	 dysfunction	 and	 ischemic	 cholangiopathy.	




This	 retrospective	 study	 used	 prospectively	 collected	 data	 collated	
from	the	UK	Transplant	Registry	and	hospital	records	on	patients	un‐
dergoing	transplantation	using	livers	recovered	from	DCD	donors	after	




vs.	12%	non‐NRP	 livers,	P	=	.0559),	 freedom	from	ischemic	cholangiopathy	 (0%	vs.	
27%	for	non‐NRP	 livers,	P	<	.0001),	and	 fewer	anastomotic	strictures	 (7%	vs.	27%	
non‐NRP, P	=	.0041).	After	adjusting	for	other	factors	in	a	multivariable	analysis,	NRP	
remained	 significantly	 associated	 with	 freedom	 from	 ischemic	 cholangiopathy	
(P	<	.0001).	These	data	suggest	that	NRP	during	organ	recovery	from	DCD	donors	
leads	to	superior	liver	outcomes	compared	to	conventional	organ	recovery.

















heart	 for	 transplantation;	 the	 abdominal	 organs	 received	 the	 same	
treatment	 in	 each	 case.	 All	 donors	 were	 controlled	 DCD	 donors	





(A‐NRP)	was	performed	by	cannulating	 the	aorta	or	 right	 common	
iliac	artery,	and	the	inferior	vena	cava	or	right	common	iliac	vein,	with	
an	endovascular	or	external	clamp	occluding	the	descending	thoracic	








The	 prime	 solution	 comprised	 compound	 sodium	 lactate	
(Hartmann's	 solution,	Baxter	Healthcare	Ltd,	Thetford,	UK)	and	suc‐




The	 circuit	 comprised	 an	 oxygenator,	 heat	 exchanger,	 pump,	
and	 latterly,	 a	 leucocyte	 filter	 (LeukoGuard,	 Pall	 Corporation,	
Portsmouth,	 UK),	 either	 using	 bespoke	 cardiopulmonary	 bypass	
equipment	from	Medtronic	(Watford,	UK),	the	Cardiohelp	(Maquet,	
Sunderland,	UK),	or	the	Extra‐Corporeal	Organ	Procurement	System	
(ECOPS)	or	 the	Donor	Assist	 (both	 from	Organ	Assist,	Groningen,	
Netherlands).	Irrespective	of	the	equipment,	the	target	for	abdom‐






preservation	 solution.	Where	 TA‐NRP	 was	 performed	 and	 cardiac	
output	was	restored,	the	extracorporeal	perfusion	was	stopped	at	30	
to	60	minutes	and	the	heart	allowed	to	support	the	limited	thoracoab‐
dominal	 circulation	while	 its	 function	was	 evaluated.	 If	 the	 cardiac	
function	was	considered	inadequate	and	failing	to	sustain	an	adequate	
mean	arterial	pressure,	extracorporeal	perfusion	was	recommenced.
The	decision	 to	use	 the	 liver	was	based	on	 subjective	 and	bio‐
chemical	 factors.	 The	 appearance	 of	 the	 liver	 during	NRP	was	 as‐
sessed,	 with	 cirrhotic	 and	 severely	 steatotic	 livers	 being	 declined.	
Alanine	transaminase	(ALT)	was	measured	in	the	perfusate	every	30	
to	60	minutes	during	NRP.	In	our	early	experience	an	ALT	over	200	












A	 contemporaneous	 comparator	 cohort	 comprised	 all	 DCD	 liver	





cholangiopancreatography	 (ERCP	 or	MRCP)	 in	 the	 absence	 of	 ar‐
terial	 thrombosis	 or	 stenosis.	 Cholangiography	 was	 undertaken	
when	clinically	indicated	by	pruritus,	cholangitis,	raised	bilirubin	or	
ALP	posttransplant.	Protocol	cholangiograms	were	also	performed	





iary	 anastomosis	 requiring	 treatment,	 and	anastomotic	 leaks	were	









range	 (continuous	 variables)	 or	 number,	 percentage	 (categorical	












STAT,	 version	 9.4	 (SAS	 Institute	 Inc.,	 Cary,	NC)	 and	 Prism	 version	
7.0c	(GraphPad,	La	Jolla,	CA).
3  | RESULTS
Between	 January	 1,	 2011	 and	 June	 30,	 2017,	 43	 DCD	 liver	
transplants	were	performed	from	70	DCD	donors	undergoing	NRP.	
These	 were	 compared	 with	 187	 non‐NRP	 DCD	 liver	 transplants	
performed	 over	 the	 same	 period.	Details	 of	 the	 donors	 are	 given	
in	Table	1,	as	are	details	of	 the	27	NRP	donors	whose	 livers	were	
not	used.	Reasons	 for	not	using	 livers	 included	donor	encephalitis	
of	unknown	cause	(n	=	1),	abnormal	liver	appearance	(n	=	7:	steato‐
sis	[n	=	3],	fibrosis,	cirrhosis,	trauma,	lesion),	thromboemboli	(n	=	3),	


















non‐NRP)	and	more	donors	dying	from	hypoxic	brain	 injury	 in	 the	
non‐NRP	comparator	 cohort	 (37%	non‐NRP,	28%	NRP),	 but	 these	
differences	were	not	significant	(P	=	.5358).	A	greater	proportion	of	
the	liver	donors	were	in	the	transplant	center	in	the	NRP	group	com‐
pared	 to	 the	non‐NRP	comparators	 (77%	vs.	16%,	P	<	.0001),	 and	
similarly	most	NRP	livers	were	retrieved	by	the	transplanting	center,	
unlike	 comparator	 livers	 (93%	 NRP	 vs.	 55%	 non‐NRP,	 P	<	.0001).	
While	the	median	withdrawal	period	was	slightly	shorter	in	the	NRP	
livers	(NRP	13	minutes,	non‐NRP	14	minutes,	P	=	.0707)	the	median	
asystolic	period	was	 slightly	 longer	 (NRP	16	minutes,	non‐NRP	13	









The	 incidence	of	early	 allograft	dysfunction,	defined	by	 the	Olthoff	
criteria,27	 was	 significantly	 lower	 in	 the	 NRP	 group	 (12%	 vs.	 32%,	
P	=	.0076),	 largely	 as	 a	 consequence	 of	 the	 significantly	 lower	 peak	
ALT	in	the	first	week	posttransplant	(633	iu/L	compared	to	1154	iu/L,	





Biliary	 complications	 were	 much	 more	 common	 in	 livers	 re‐
covered	without	NRP.	Of	the	171	non‐NRP	liver	recipients	whose	
livers	 lasted	more	 than	8	days,	26	 (15%)	developed	both	anasto‐
motic	strictures	and	ischemic	cholangiopathy,	21	(12%)	developed	
ischemic	 cholangiopathy	 alone,	 and	 21	 (12%)	 anastomotic	 stric‐
tures	 alone.	Where	NRP	was	used,	none	of	 the	 recovered	 livers	
developed	 cholangiopathy	 compared	 to	 a	 27%	 total	 incidence	
of	 cholangiopathy	 in	 non‐NRP	 livers	 (P	<	.0001).	 7%	of	 the	NRP	
DCD	livers	developed	an	anastomotic	stricture	compared	to	a	27%	
anastomotic	 stricture	 rate	 in	 the	 comparator	 group	 (P	=	.0069).	
The	actual	90‐day	death‐censored	graft	survival	and	patient	sur‐
vival	were	 comparable	between	groups,	 although	 the	5‐year	 ac‐
tuarial	 death‐censored	graft	 survival	was	 significantly	better	 for	






the	 non‐NRP	 liver	 recipients,	 the	 difference	 in	 CKD‐GFR	 did	 not	
reach	significance	(P	=	.6229;	Table	2).
3.3 | Factors determining ischemic cholangiopathy




Tables	3‐5	 detail	 the	 recipient,	 donor	 and	 transplant	 factors	
considered.	Recipients	who	developed	cholangiopathy	had,	on	aver‐
age,	a	lower	serum	sodium	at	the	time	of	transplant.	Donors	whose	
     |  5WATSON eT Al.















Head	injury 23	(12%) 10	(23%) 5	(18%) .5358
Hypoxia 69	(37%) 12	(28%) 8	(30%)
Cerebrovascular	accident 90	(48%) 20	(47%) 13	(48%)
Other 5	(3%) 1	(2%) 1	(4%)
Agonal	period	(minutes)b	(median,	IQR) 14	(10‐18) 13	(11‐17) 18	(10‐89) .0707
Asystolic	period	(minutes)b 13	(11‐16) 16	(13‐20) 17	(13‐22) <.0001
Withdrawal	to	in	situ	perfusion	(minutes)b 27	(22‐32) 30	(26‐36) 34	(24‐108) .0046
Normothermic	regional	perfusion	duration	(minutes)c	(median;	IQR) 123	(103‐130) 122	(86‐127) .3657
Cold	ischemic	period	(minutes)d 444	(395‐493) 382	(303‐502) .0035
Preservation	period	(minutes)c 444	(395‐493) 510	(423‐631) .0008
US	donor	risk	indexc 2.5	(2.0‐2.9) 1.8	(1.7‐2.4) <.0001
UK	donor	liver	indexe 1.9	(1.6‐2.2) 1.9	(1.7‐2.2) 2.0	(1.8‐2.5) .4275
Location	of	donor <.0001
Local 29	(16%) 33	(77%) 18	(67%)
Regional 68	(36%) 10	(23%) 9	(33%)

















F I G U R E  1  Duration	of	NRP,	cold	
ischemia,	and	total	preservation.	NRP,	
normothermic	regional	perfusion
6  |     WATSON eT Al.
recipients	developed	cholangiopathy	were	on	average	older,	had	a	
lower	peak	ALT	before	donation,	spent	 less	time	on	intensive	care	






A	 logistic	 regression	model	was	then	built	 to	 identify	 the	odds	
of	 developing	 IC.	Donor	 age,	 the	 recipient	 sodium	 and	 locality	 of	
the	liver	predicted	the	development	of	IC	posttransplant	(Table	6).	
















livers	 following	 transplantation,	 so	 much	 so	 that	 no	 liver	 from	 a	
donor	undergoing	NRP	prior	to	recovery	developed	cholangiopathy.	
Our	study	has	also	shown	that	 lower	 recipient	sodium	at	 the	time	
of	surgery,	older	donor	age,	and	a	donor	outside	the	local	hospital	


































Our	 cholangiopathy	 data	 mirror	 the	 Spanish	 experience	 pre‐




that	 study	 also	 (87%	NRP,	 78%	 non‐NRP).30	 Assuming	 the	 appar‐
ent	difference	 in	cholangiopathy	rates	 is	 real,	and	the	presence	of	







F I G U R E  2  Box	and	whisker	plot	showing	difference	in	model	for	
early	allograft	function	(MEAF)	score	between	groups
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Recipient	age	(median,	IQR,	range) 60	(51‐64;	34‐73) 57	(51‐63;	18‐72) .3192
Liver	disease	necessitating	transplant








UKELD	at	transplant	(median	[IQR])a 56	(52‐59) 54	(50‐58) .2389
MELD	at	transplant	(median	[IQR])c 15	(12‐23) 15	(11‐20) .4169
Peak	ALT	in	first	7	d	(median	[IQR]) 633	(319‐1070) 1154	(667‐2099) <.0001
Early	allograft	dysfunctionc 5/43	(12%) 55/173	(32%) .0076
Model	for	early	allograft	function	(median	[IQR])f 3.5	(2.4‐5.1) 5.0	(3.8‐6.6) <.0001
Bile	duct	complicationsd
Biliary	leak 3/43	(7%) 18/174	(10%) .7731
Anastomotic	stricture 3/42	(7%) 46/171	(27%) .0041
Ischemic	cholangiopathy 0/42	(0%) 47/171	(27%) <.0001
Proportion	undergoing	cholangiography	(M/ERCP) 13/42	(31%) 91/171	(53%) .0102
Graft	loss
Primary nonfunction 0 13	(7%)e .1347
Hepatic	artery	thrombosis	in	first	28	d 1	(2%) 5	(3%) >.99
Ischemic	cholangiopathy 0 11	(6%) .2253














































Several	 additional	 observations	 are	 noteworthy.	 The	 non‐NRP	
livers	suffered	a	numerically	higher	(7%)	incidence	of	primary	non‐
function,	 compared	 to	 no	 primary	 nonfunction	 in	 the	 NRP	 livers	
(P	=	.1347).	This	is	in	spite	of	the	liver	utilization	rate	in	NRP‐treated	
livers	being	61%,	 in	contrast	 to	 the	UK	national	 rate	without	NRP	
which	 varied	 between	 27%	 and	 36%	 per	 annum	 in	 the	 period	 of	
the	 study,1,36	 suggesting	 that	 selection	 bias	was	 probably	 not	 the	
reason	for	the	better	initial	outcomes.	Instead	the	difference,	albeit	


















from	 the	 start.	 In	 two	other	 cases	clots	were	noted	 in	 the	circuit,	
in	one	case	associated	with	the	leucocyte	filter	and	in	the	other	in	





P‐valueNo missing Median (IQR) No missing Median (IQR) No missing Median (IQR)
Recipient factors
Age	(y) 0 58	(54‐62) 0 57	(51‐63) 0.9 0 57	(51‐63)
Creatinine	(μmol/L) 0 69	(56‐89) 0 74	(63‐95) 0.2 0 73	(62‐95)
Bilirubin	(μmol/L) 0 46	(30‐83) 0 43	(20‐88) 0.5 0 43.5	(22‐86)
International	normal‐
ised	ratio	(INR)
0 1.4	(1.2‐1.6) 0 1.4	(1.14‐1.6) 0.7 0 1.4	(1.14‐1.6)
Sodium	(mmol/L) 0 135	(132‐138) 0 137	(134‐139) 0.01 0 136	(134‐139)
Potassium	(mmol/L) 1 4.2	(4‐4.5) 2 4.1	(3.9‐4.5) 0.6 3 4.1	(3.9‐4.5)
Albumin	(gm/L) 1 29	(25‐34) 1 29	(25‐33) 0.6 2 29	(25‐34)
Waiting	time	to	
transplant	(d)
0 94	(23‐248) 4 74	(28‐183) 0.4 4 77.5	(26‐193)
Donor	factors







Donor	height	(cm) 0 172	(167‐177) 0 172	(165‐179) 0.97 0 172	(165‐178)
Maximum	ALT	(iu/L) 0 29	(20‐55) 4 40	(22‐84) 0.04 4 36	(21‐73)
Maximum	bilirubin	
(μmol/L)
0 9	(6‐12) 0 9	(6‐14) 0.4 0 9	(6‐14)
ITU	stay	(d) 0 2	(1‐4) 2 3	(2‐5) 0.04 2 3	(2‐5)
Hospital	stay	prior	to	
donation	(d)
0 3	(1‐5) 0 3	(2‐5) 0.12 0 3	(2‐5)
10  |     WATSON eT Al.







of	 the	 blood	with	 the	 heparinized	 prime	 solution	 had	 occurred,10 
while	Edinburgh	also	used	heparin‐coated	components	in	its	circuit.	




























HCV	status No	HCV 38	(80.9%) 136	(74.3%) .4
HCV 9	(19.1%) 47	(25.7%)
Renal support Hemodialysis 1	(2.1%) 13	(7.1%) .6
Hemofiltration 0	(0%) 2	(1.1%)
Not	required 46	(97.9%) 166	(91.8%)





No 43	(91.5%) 158	(86.3%) .5
Yes 4	(8.5%) 25	(13.7%)














Ascites No	ascites 24	(51.1%) 102	(55.7%) .6
Ascites 23	(48.9%) 81	(44.3%)
Diabetes No 33	(70.2%) 126	(68.9%) .9
Yes 14	(29.8%) 53	(29.0%)
Not	reported 0	(0%) 4	(2.2%)
TA B L E  4  Summary	of	categorical	
recipient	factors	for	231	DCD	donor	livers	
transplanted	by	ischemic	cholangiopathy
     |  11WATSON eT Al.










Donor	sex Male 28	(59.6%) 110	(60.1%) >.99
Female 19	(40.4%) 73	(39.9%)
Donor	ethnicity White 46	(97.9%) 177	(96.7%) >.99
Asian 1	(2.1%) 6	(3.3%)
History	of	diabetes No 45	(95.7%) 174	(95.1%) >.99
Yes 2	(4.3%) 8	(4.4%)
Unknown 0	(0%) 1	(0.5%)
History	of	smoking No 23	(48.9%) 99	(54.1%) .6
Yes 24	(51.1%) 84	(45.9%)
Organ	appearance Healthy 35	(74.5%) 147	(80.3%) .4
Suboptimal 12	(25.5%) 33	(18%)
Unknown 0	(0%) 3	(1.6%)
Steatosis No 27	(57.4%) 113	(61.7%) .8
Yes 20	(42.6%) 67	(36.6%)
Unknown 0	(0%) 3	(1.6%)


































tion	 but	which	 previously	would	 have	 been	 used	 based	 solely	 on	
predonation data.
In	 summary,	 we	 have	 described	 43	 cases	 of	 liver	 transplanta‐
tion	from	DCD	donors	subject	to	NRP,	with	improved	early	allograft	
function,	 absence	of	 ischemic	 cholangiopathy,	 and	 improved	 graft	
survival.	The	multivariate	analysis	emphasizes	the	potential	of	NRP	


















at	 the	 University	 of	 Cambridge	 in	 collaboration	 with	 Newcastle	
University	 and	 in	 partnership	 with	 NHS	 Blood	 and	 Transplant	









P‐valueNo missing Median (IQR) No missing Median (IQR) No missing Median (IQR)
Asystolic	perioda 1 14	(12‐16) 0 13	(11‐16) 0.4 0 13	(11‐16)
Withdrawal	period	
(min)b
0 28	(22‐32) 2 28	(23‐33) 0.7 0 28	(22‐33)
Cold	ischaemia	
time	(min)
0 428	(385‐477) 2 438	(382‐499) 0.94 0 433.5	(383‐496.5)
aAsystolic	period:	circulatory	arrest	to	in	situ	cold	perfusion	with	preservation	solution	or	commencement	of	NRP.	
bWithdrawal	period,	from	withdrawal	of	treatment	to	circulatory	arrest.	





Donor	age	(y) Linear 207 1.03	(1.00,	
1.06)
.015























Identical 46	(97.9%) 181	(98.9%) .5
Compatible 1	(2.1%) 2	(1.1%)
Perfusion used Comparator 47	(100%) 140	(76.5%) <.0001
NRP 0	(0%) 43	(23.5%)
TA B L E  5   (Continued)
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